CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
022410Orig1s000

SUMMARY REVIEW
## Summary Review for Regulatory Action

<table>
<thead>
<tr>
<th>Date</th>
<th>August 30, 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>From</td>
<td>Rigoberto Roca, M.D.</td>
</tr>
<tr>
<td></td>
<td>Deputy Director</td>
</tr>
<tr>
<td></td>
<td>Division of Anesthesia and Analgesia Products</td>
</tr>
<tr>
<td>Subject</td>
<td>Deputy Division Director Summary Review</td>
</tr>
<tr>
<td>NDA Number</td>
<td>022410</td>
</tr>
<tr>
<td>Applicant Name</td>
<td>Reckitt Benckiser</td>
</tr>
<tr>
<td>Date of Original Submission</td>
<td>October 21, 2008</td>
</tr>
<tr>
<td>Date of Complete Response</td>
<td>August 21, 2009</td>
</tr>
<tr>
<td>Date of Re-Submission</td>
<td>November 30, 2009</td>
</tr>
<tr>
<td>PDUFA Goal Date</td>
<td>August 30, 2010 (extended due to a submission of a major amendment)</td>
</tr>
<tr>
<td>Proprietary Name / Established (USAN) Name</td>
<td>Suboxone (Buprenorphine/naloxone) sublingual film</td>
</tr>
<tr>
<td>Dosage Forms / Strength</td>
<td>Sublingual film</td>
</tr>
<tr>
<td></td>
<td>2 mg/0.5 mg and 8 mg/2 mg</td>
</tr>
<tr>
<td>Proposed Indication(s)</td>
<td>For the maintenance treatment of opioid dependence (b) (4)</td>
</tr>
<tr>
<td>Action</td>
<td>Approval</td>
</tr>
</tbody>
</table>

### Material Reviewed/Consulted

<table>
<thead>
<tr>
<th>OND Action Package, including:</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDTL Review</td>
</tr>
<tr>
<td>DDMAC</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>OSE/DMEPA</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>OSE/DRISK</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Office of Compliance</td>
</tr>
</tbody>
</table>

CDTL = Cross-Discipline Team Leader
DDMAC = Division of Drug Marketing, Advertising and Communication
DMEPA = Division of Medication Error Prevention and Analysis
DRISK = Division of Risk Management
OND = Office of New Drugs
OSE = Office of Surveillance and Epidemiology
DSI = Division of Scientific Investigations
1. Introduction

The Applicant, Reckitt Benckiser, submitted an application on October 21, 2008, for a line extension of, and as an alternative to, their Suboxone tablets. The new formulation is a sublingual strip, in dosage strengths that are similar to the approved tablets; specifically, buprenorphine 2 mg/naloxone 0.5 mg and buprenorphine 8 mg/naloxone 2 mg. The application received a Complete Response on August 21, 2009, because it did not contain an adequate Risk Evaluation and Mitigation Strategy (REMS) to address the Agency’s concerns regarding misuse and abuse of the product. The Applicant’s submission of November 24, 2009, constituted a Complete Response to the Action letter of August 21, 2009.

This review will provide an overview of the regulatory and scientific facts of this application and issues that were identified during the course of the review of the submission. Aspects that will be touched upon include the regulatory history, the adequacy of the data to support the application, and the labeling requested by the Applicant.

2. Background

Buprenorphine is an opioid partial agonist which has been marketed as an injectable analgesic since 1982. Subutex (buprenorphine) and Suboxone (buprenorphine and naloxone) were approved in 2002 for the treatment of opioid dependence. These products may only be prescribed by health care professionals who have fulfilled certain training requirements defined in the Drug Abuse Treatment Act of 2002, which also limits the number of patients for whom a specific health care professional or group practice may prescribe these products. As noted in Dr. Rappaport’s memorandum from the first review cycle, due to its pharmacological properties, buprenorphine, with or without naloxone, has been thought to be useful only in patients with mild to moderate degrees of opioid dependence. Methadone remains the treatment of choice for patients with more severe forms of opioid addiction.

Dr. Rappaport also noted that the Applicant purportedly created this formulation to minimize abuse and misuse, including unintended exposures in children. The Applicant also posited an increase in patient compliance, minimization of counterfeiting, minimization of illegal use and diversion, and a decrease in product damage during transport and storage compared to the sublingual tablets. These goals were based on the use of unit dose packaging and child-resistant packaging with improved coding.

Support for the efficacy and safety of this product rested primarily on data from Phase 1 pharmacokinetic studies evaluating bioavailability, dose proportionality, and comparisons to Suboxone tablets, and reference to the sponsor’s NDAs for Suboxone and Subutex. A small open-label safety study of the buprenorphine/naloxone strip and a small laboratory study comparing the buprenorphine/naloxone strip to a buprenorphine-only strip supplemented these findings.
3. Chemistry, Manufacturing, and Controls (CMC)
All issues related to product quality, facilities review and inspections, as well as stability testing were addressed during the first review cycle. There were no outstanding issues that would have precluded approval, and no new information was submitted or reviewed with this submission.

4. Nonclinical Pharmacology/Toxicology
No new nonclinical pharmacology/toxicology information was submitted or reviewed in this submission. Label changes recommended by the pharmacology/toxicology reviewer based on the initial application are documented in the original reviews and will be incorporated in labeling.

5. Clinical Pharmacology/Biopharmaceutics
No new nonclinical clinical pharmacology/biopharmaceutics information was reviewed in this submission. Labeling changes recommended by the reviewer based on the initial application are documented in the original reviews and will be incorporated in labeling.

Hepatic impairment:
The Applicant has an outstanding post-marketing commitment under the NDAs for Subutex (NDA 020732) and Suboxone (NDA 020733) to study the effects of hepatic impairment on the pharmacokinetics of buprenorphine/naloxone. This study has not been initiated and it will be reiterated with this approval as a post-marketing requirement for this NDA.

Thorough QT Study
As noted in Dr. Winchell’s review, there were no new electrocardiographic data reviewed in the original submission. The Applicant had submitted data on electrocardiograms collected during the pharmacokinetic studies; however, these data were not expected to yield any information relevant to the application because they were collected from healthy volunteers and not in the same manner and degree were a determination could be made on the effect of the QT interval.

Since the action was taken on August 21, 2009, the Agency has become aware of the results of a thorough QT (TQT) study conducted by Purdue Pharma with their transdermal buprenorphine product (BuTrans, NDA 021306). In this study, transdermal application of buprenorphine, 10 mcg/hr and 40 mcg/hr, were compared to a moxifloxacin control. (b)(4)

Dr. Winchell also noted in her review that there have been other studies reported in the literature, conducted with buprenorphine at typical addiction treatment doses and appropriate ECG measurements, which do not indicate a clinically significant effect on the QT interval.
Outstanding or Unresolved Issues

The Applicant will be required to conduct a thorough QT study. This can be accomplished as a post-approval study, and will be identified as a post-marketing requirement in the action letter.

6. Clinical Microbiology

The drug product, buprenorphine/naloxone, is not a therapeutic antimicrobial; therefore, clinical microbiology data were not required or submitted for this application.

7. Clinical/Statistical-Efficacy

There were no new efficacy data submitted in support of this application, and none were needed in support of the complete response submission.

8. Safety

As noted in Dr. Winchell’s review of the original submission, the safety review of the application consisted of:

1. Data generated in the Applicant’s safety study, RB-US-07-0001.
2. Data generated in the Applicant’s laboratory induction study, RB-US-07-0002.
3. The Applicant’s comprehensive evaluation of hepatic safety issues, comprising their evaluation of sources such as postmarketing data, literature, and clinical trial data. This review was supplemented by a review of AERS data conducted by the Office of Surveillance and Epidemiology (OSE).
4. The Applicant’s evaluation of issues related to the use of buprenorphine in pregnancy.
5. The Applicant’s evaluation of information about accidental pediatric exposure, which was submitted to substantiate the public health importance of the individually-packaged strip product.

Dr. Rappaport’s noted in his memorandum that there were no serious or unexpected safety signals identified during the first review cycle. However, three concerns were noted by the review team:

- Potential for oral mucosal irritation;
- Potential to precipitate withdrawal in the opioid dependent patients who would be treated by this product; and
- Potential for hepatotoxicity.

Dr. Rappaport noted that the incidence of withdrawal symptoms in the overall database was no higher than would be expected in this patient population, and, therefore, generally not concerning. He also noted that, while there was no new or increased hepatotoxicity signal noted in the database, the previous post-marketing commitment to evaluate the comparative effects of buprenorphine and methadone on the liver should be reiterated.
During this review cycle, which included a safety update, the overall conclusion regarding the safety profile of the product was essentially unchanged from the conclusion reached during the first review cycle.

Regarding the potential for oral mucosal irritation, the review team has concluded that routine pharmacovigilance of the post-marketing adverse event reports should be sufficient to determine whether a specific post-marketing study would be warranted and I concur.

Regarding the potential for hepatic toxicity, it was noted that, at the time of this submission, a study was already underway to evaluate the comparative hepatic safety of buprenorphine and methadone. This was the study identified by Dr. Rappaport in his memorandum as one of the post-marketing commitments agreed to by the Applicant under the NDAs for Subutex and Suboxone (NDAs 020732 and 020733, respectively).

Another outstanding post-marketing commitment under the NDAs for Subutex and Suboxone was a study to evaluate the effects of hepatic impairment on the pharmacokinetics of buprenorphine/naloxone. This study has not been initiated and will be reiterated as a post-marketing requirement with this action.

**Outstanding or Unresolved Issues**

The Applicant has a study underway comparing the hepatic safety of buprenorphine and methadone under the sponsorship of the National Institute on Drug Abuse. This study was a post-marketing commitment under the NDAs for Subutex (NDA 020732) and Suboxone (NDA 020733).

The Applicant will have two post-marketing requirements imposed with this action: one to evaluate the effects of hepatic impairment on the pharmacokinetics of buprenorphine/naloxone, and one to conduct a thorough QT study (as described above, in the Clinical Pharmacology/Biopharmaceutics section of this memorandum).

**9. Advisory Committee Meeting**

As noted in Dr. Rappaport’s memo, the review team determined that an advisory committee meeting was unnecessary for this new formulation of buprenorphine/naloxone as there were no clinically serious new or unexpected safety concerns specific to this product.

**10. Pediatrics**

This product is exempt from the pediatric study requirements authorized by PREA as the sponsor received orphan designation for the active moiety of buprenorphine, with or without naloxone, for the treatment of opioid addiction.
11. **Other Relevant Regulatory Issues**

The Complete Response action that was taken after the first review cycle was due to the lack of an adequate REMS submission. The action letter indicated that the REMS must include the following:

1) Medication Guide
2) Elements to Assure Safe Use
   a) including, at least, assurance that each patient using the drug is subject to certain clinical monitoring under section 505-1(f)(3)(E) of the FDCA to ensure that
      i) each patient is receiving the psychosocial support necessary for safe and effective use buprenorphine,
      ii) each patient adheres to the conditions of safe use explained to him/her, and
      iii) each patient is using Suboxone sublingual film appropriately and making adequate progress towards treatment goals.
3) Timetable for Submission of Assessment

The final version of the REMS submitted by the Applicant has met these stipulations.

4) **Labeling**

The Applicant has submitted enough information to support their proposed labeling. As noted above, representatives from the Office of Surveillance and Epidemiology and the Division of Drug Marketing, Advertising and Communications were consulted and their recommendations were incorporated during the discussion of the label.

The label has been revised in several ways to more strongly emphasize the drug, and the risk of accidental exposure. It also includes more explicit recommendations on clinical management in the Dosing and Administration section.

5) **Decision/Action/Risk Benefit Assessment**

   **Regulatory Action**  
   Approval.

   **Risk:Benefit Assessment**
   I concur with the review team that the Applicant has submitted sufficient evidence to demonstrate the effectiveness and safety of the new formulation when used according the labeled instructions. With the submission of an acceptable REMS, the Applicant has addressed the Agency’s concerns regarding misuse and abuse of the product, and, therefore, I find the risk:benefit assessment favorable.

   **Recommendation for Postmarketing Risk Management Activities**
   In order to assure that the benefits of this product outweigh the risks of abuse, misuse and accidental pediatric exposure, the Agency has determined that the product must have a REMS as described above. The REMS is comprised of a Medication Guide, an Element to Assure Safe Use (ETASU), and a timetable for
Submission of assessments of the REMS. The ETASU falls under section 505-1(f)(3)(E) of the FDCA and is intended to ensure that 1) each patient is receiving the psychosocial support necessary for safe and effective use of buprenorphine, 2) each patient adheres to the conditions of safe use explained to him/her, and 3) each patient is using Suboxone sublingual film appropriately and making adequate progress towards treatment goals.

Recommendation for other Postmarketing Study Requirements

1. The Applicant will need to conduct a clinical trial to assess the risk of QT prolongation with their buprenorphine-containing product, i.e., a thorough TQT trial. This trial should include a methadone treatment arm, at typical treatment doses, for comparison. It is likely that this trial will need to be conducted in opioid-tolerant volunteers or new entrants to opioid dependence treatment.

2. The Applicant will need to conduct a clinical trial to determine the effect of hepatic impairment on the pharmacokinetics of their buprenorphine-containing product, and to establish whether there is a differential effect on the buprenorphine as compared to naloxone.

Recommendation for other Postmarketing Study Commitments

None.
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-22410</td>
<td>ORIG-1</td>
<td>RECKITT BENCKISER PHARMACEUTICA LS INC</td>
<td>SUBOXONE (BUPRENORPHINE/NALOXONE) sublingual film</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
RIGOBERTO A ROCA
08/30/2010